Page 142 - 2019_10 resto del Mondo_web

R. Bassan et al.
References
1. Carroll W, Loh M, Biondi A, Willman C. The biology of acute lymphoblastic leukemia In: Reaman G, Smith F, eds. Childhood Leukemia: a Practical Handbook. Berlin and Heidelberg: Springer-Verlag. 2011:29–61.
2. Cancer Research UK. Types of acute lym- phoblastic leukaemia. 2015. Available from: http://www.cancerresearchuk.org/about- cancer/acute-lymphoblastic-leukaemia- all/types (Accessed 24 May 2016).
3. Fielding AK. Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2011;2011(1): 231–237.
4. Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnor- malities in adult acute lymphoblastic leukemia. Blood. 1998;91(11):3995–4019.
5. Iacobucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol. 2017;35(9):975–983.
6. Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl 5):v69–v82.
7. Parikh SA, Litzow MR. Philadelphia chro- mosome-negative acute lymphoblastic leukemia: therapies under development. Future Oncol. 2014;10(14):2201–2212.
8. Zhang H, Gu L, Liu T, Chiang KY, Zhou M. Inhibition of MDM2 by nilotinib con- tributes to cytotoxicity in both Philadelphia- positive and negative acute lymphoblastic leukemia. PLoS One. 2014;9(6):e100960.
9. Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–847.
10. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–753.
11. Martinelli G, Boissel N, Chevallier P, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromo- some-positive B-precursor acute lym- phoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 2017;35(16):1795–1802.
12. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5):532–543.
13. Hoelzer D. Personalized medicine in adult acute lymphoblastic leukemia. Haematologica. 2015;100(7):855–858.
14. Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002;99(3):863–871.
15. Gökbuget N, Hoelzer D, Arnold R, et al. Treatment of adult ALL according to proto- cols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am. 2000;14(6):1307– 1325, ix.
16. Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood. 1995;85(8):2025–2037.
17. Rowe JM, Buck G, Burnett AK, et al.
Induction therapy for adults with acute lym- phoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106(12):3760–3767.
18. Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22(20):4075–4086.
19. Chen X, Xie H, Wood BL, et al. Relation of clinical response and minimal residual dis- ease and their prognostic impact on out- come in acute myeloid leukemia. J Clin Oncol. 2015;33(11):1258–1264.
20. Gökbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor progno- sis and are candidates for stem cell trans- plantation and targeted therapies. Blood. 2012;120(9):1868–1876.
21. Scheuring UJ, Pfeifer H, Wassmann B, et al. Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treat- ment. Leukemia. 2003;17(9):1700–1706.
22. Bassan R, Intermesoli T, Scattolin A, et al. Minimal residual disease assessment and risk-based therapy in acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2017;17S:S2–S9.
23. Brown PA, Shah B, Advani A, et al. NCCN clinical practice guidelines in oncology with NCCN evidence blocks. Acute lymphoblas- tic leukemia. Version I.2018 – December 13, 2018. Available from: https://www.nccn.org/professionals/physi- cian_gls/pdf/all_blocks.pdf (Accessed 31 January 2019).
24. Short NJ, Jabbour E, Albitar M, et al. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: a consensus of North American experts. Am J Hematol. 2019;94(2):257–265.
25. European Medicines Agency. Guideline on the use of minimal residual disease as a clin- ical endpoint in multiple myeloma studies. 2018. Available from: https://www.ema.europa.eu/documents/sci entific-guideline/draft-guideline-use-mini- mal-residual-disease-clinical-endpoint-mul- tiple-myeloma-studies_en.pdf (Accessed 25 October 2018).
26. Food and Drug Administration. Hematologic malignancies: regulatory con- siderations for use of minimal residual dis- ease in development of drug and biological products for treatment – guidance for indus- try. 2018. Available from: https://www.fda.gov/downloads/Drugs/Gu idanceComplianceRegulatoryInformation/ Guidances/UCM623333.pdf (Accessed 25 October 2018).
27. Bruggemann M, Kotrova M. Minimal resid- ual disease in adult ALL: technical aspects and implications for correct clinical interpre- tation. Blood Adv. 2017;1(25):2456–2466.
28. Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3(7):e170580.
29. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explana- tion and elaboration. Ann Intern Med. 2009;339:b2700.
30. Tierney JF, Stewart LA, Ghersi D, Burdett S,
Sydes MR. Practical methods for incorporat- ing summary time-to-event data into meta- analysis. Trials. 2007;8:16.
31. Bachanova V, Marks DI, Zhang MJ, et al. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplanta- tion: impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia. 2014;28(3):658–665.
32. Giebel S, Stella-Holowiecka B, Krawczyk- Kulis M, et al. Status of minimal residual dis- ease determines outcome of autologous hematopoietic SCT in adult ALL. Bone Marrow Transplant. 2010;45(6):1095–1101.
33. Tucunduva L, Ruggeri A, Sanz G, et al. Impact of minimal residual disease on out- comes after umbilical cord blood transplan- tation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia work- ing party of the European Group for Blood and Marrow Transplantation. Br J Haematol. 2014;166(5):749–757.
34. Nishiwaki S, Imai K, Mizuta S, et al. Impact of MRD and TKI on allogeneic hematopoi- etic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT. Bone Marrow Transplant. 2016;51(1):43–50.
35. Wassmann B, Pfeifer H, Stadler M, et al. Early molecular response to posttransplanta- tion imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2005;106(2): 458–463.
36. Goekbuget N, Kantarjian H, Brüggemann M, et al. An evaluation of molecular response in a phase 2 open-label, multicen- ter confirmatory study in patients (pts) with relapsed/refractory B-precursor acute lym- phoblastic leukemia (r/r ALL) receiving treatment with the BiTE® antibody con- struct blinatumomab Blood. 2014;124 (21):3704.
37. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3): 177–188.
38. Whitehead A. Meta-Analysis of Controlled Clinical Trials. Chichester, UK: John Wiley & Sons, Ltd, 2003.
39. Hardy RJ, Thompson SG. Detecting and describing heterogeneity in meta-analysis. Stat Med. 1998;17(8):841–856.
40. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta- analyses. BMJ. 2003;327(7414):557–560.
41. Gökbuget N, Dombret H, Bonifacio M, et al. Long-term outcomes after blinatumomab treatment: follow-up of a phase 2 study in patients (pts) with minimal residual disease (MRD) positive B-cell precursor acute lym- phoblastic leukemia (ALL). Blood. 2015;126(23):680 (abstract).
42. Chiaretti S, Vitale A, Elia L, et al. Multicenter total therapy Gimema LAL 1509 protocol for de novo adult Ph+ acute lymphoblastic leukemia (ALL) patients. Updated results and refined genetic-based prognostic stratifi- cation. Blood. 2015;126(23):81.
43. Jabbour E, Short NJ, Jorgensen JL, et al. Differential impact of minimal residual dis- ease negativity according to the salvage sta- tus in patients with relapsed/refractory B- cell acute lymphoblastic leukemia. Cancer. 2017;123(2):294–302.
44. Ravandi F, Jorgensen JL, O'Brien SM, et al. Minimal residual disease assessed by multi- parameter flow cytometry is highly prog- nostic in adult patients with acute lym- phoblastic leukaemia. Br J Haematol.
2038
haematologica | 2019; 104(10)